Axogen outlines at least $270M 2026 revenue on at least 20% growth amid Avance biologic channel transition
Source: SeekingAlpha
2026-04-28 17:42:26 ET
More on AxoGen
- Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
- Axogen, Inc. 2026 Q1 - Results - Earnings Call Presentation
- Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
- AxoGen Non-GAAP EPS of $0.07 in-line, revenue of $61.46M beats by $3.69M
- Axogen targets at least 18% revenue growth in 2026 as BLA milestone strengthens market position
Read the full article on Seeking Alpha
For further details see:
Axogen outlines at least $270M 2026 revenue on at least 20% growth amid Avance biologic channel transition
Axogen Inc.
NASDAQ: AXGN
AXGN Trading
2.74% G/L:
$43.725 Last:
346,064 Volume:
$42.34 Open:
AXGN Latest News
April 30, 2026 04:43:11 pm
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
April 30, 2026 07:00:00 am
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
AXGN Stock Data
$1,718,521,634
48,724,023
1.05%
75
N/A
Medical Equipment & Supplies
Healthcare
US
Alachua
